The Pharma Landscape Is Changing

It is amazing how quickly developments move through the biotech and pharma sectors. Two years ago, Valeant Pharmaceuticals VRX was a serial acquirer of off-patent drugs, a hedge fund model and market darling that traded at $250 a share.

Its model, which involved significant price hikes, has since been discredited and the company is selling off assets to pare down the huge debt it took on to make acquisitions. The stock trades at under 10 cents on the dollar to where it was this time in 2015. Many others in the same sub-sector, like Endo Pharmaceuticals ENDP, have also suffered greatly....388 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.